Certified Peptides Launches Dedicated Site for KLOW Peptide Blend as Search Interest Surges

San Diego, United States, 5th November – Certified-PEP, a US based supplier of research-use-only (RUO) peptides, today announced the launch of a dedicated sister site for its KLOW Peptide Blend. The new site is built to help researchers and curious readers better understand the compound.  The new KLOW resource center can be found at: https://klowpeptideblend.us.com/ 

The launch follows a sharp rise in interest. U.S. search data shows “klow peptide” climbing steadily over the past year, to roughly 140,000 monthly searches. Pincpeptide reports that “klow peptide” and “wolverine stack” were among the rising U.S. Google searches related to “bpc 157” in the 12 months to September 29, 2026. Because the blend now draws more attention than almost any other peptide product, Certified-PEP chose to give it its own home instead of folding it into the main catalog.

“People are searching for KLOW in large numbers, and a lot of what they find is confusing or incomplete,” said Benson Jamison of Certified Peptides. “We built a standalone site so anyone looking into this blend can find clear, organized information in one place.”

A Fast-Growing Category

Public interest in peptides is growing quickly:

• A November 2025 KFF poll found about 1 in 8 U.S. adults (12%) said they were taking a peptide.
• A May 2026 Hone Health survey of 2,491 peptide-aware U.S. adults found 83% support letting licensed compounding pharmacies make popular peptides with a prescription. 39% said FDA reclassification would be the biggest reason they would try peptides or use them more.
• New Beauty’s 2026 State of Aesthetics research found only 12.3% of beauty consumers recognize BPC-157, even as 47.9% of peptide users spend $1,000 or more a year on peptide therapies or weight-loss drugs.
• Grand View Research valued the global peptide therapeutics market at $140.9 billion in 2025 and projects it will reach $294.6 billion by 2033. That figure is driven largely by approved drugs such as GLP-1s, not research peptides.

The Regulatory Picture

The regulatory landscape is also changing. In April 2026, the FDA removed 12 peptides from its Category 2 “significant safety risk” list, including BPC-157, TB-500, KPV, and injectable GHK-Cu. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, TB-500, and KPV for the 503A bulk drugs list. Injectable GHK-Cu is due for review before the end of February 2027.

Removal from Category 2 does not make a peptide approved or eligible for compounding. All Certified-PEP products, including KLOW Peptide Blend, are sold strictly for laboratory research use and are not for human consumption.

New Research Content

Alongside the launch, Certified-PEP has been publishing new educational material. Readers can explore the latest articles on the Certified-PEP research blog.

Learn More

To learn more about KLOW Peptide Blend, visit https://klowpeptideblend.us.com/

Certified-PEP is a U.S.-based supplier of peptides and compounds for qualified laboratory research. The company emphasizes U.S. manufacturing, batch-specific analytical testing through Vanguard Laboratory, product labeling with COA information, transparent research documentation and top-tier customer service. Certified-PEP products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use or clinical applications. Find more at: https://certified-pep.com/

Research Use Only: Certified-PEP products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use, consumption, clinical use, diagnosis, treatment or prevention of disease.

About KLOW Peptide Blend

KLOW Peptide Blend is a research compound offered by Certified-PEP, a U.S.-based supplier of peptides and compounds for qualified laboratory research. The dedicated KLOW site gives researchers a central place to learn about the blend, with organized educational content and product documentation. KLOW Peptide Blend is intended solely for in-vitro laboratory research and is not intended for human or veterinary use or clinical applications. Find more at: https://klowpeptideblend.us.com/